Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Alzheimer disease

Elevated neurogranin levels reveal early synaptic damage in APOE* ɛ4 carriers

Nature Reviews Neurology volume 12, page 430 (2016)Cite this article

Subjects

Access through your institution
Buy or subscribe

Levels of neurogranin are elevated in the cerebrospinal fluid of people with mild cognitive impairment who carry the apolipoprotein E (APOE) ɛ4 allele, new research has shown. APOE* ɛ4 is the most important genetic risk factor for AD, but the pathophysiological link between the risk allele and AD has remained elusive. Neurogranin is a marker of synaptic injury, and the new data suggest that APOE* ɛ4 carriers are susceptible to synaptic damage manifests as cognitive decline.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sun, X. et al. APOE ɛ4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease. Alzheimers Dement. http://dx.doi.org/10.1016/j.jalz.2016.05.003 (2016)

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elevated neurogranin levels reveal early synaptic damage in APOE* ɛ4 carriers. Nat Rev Neurol 12, 430 (2016). https://doi.org/10.1038/nrneurol.2016.102

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneurol.2016.102

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing